REG - Beximco Pharma. - Notification of Preliminary Results and AGM

Beximco PharmaceuticalsAnnouncement

29/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241029:nRSc9176Ja&default-theme=true

RNS Number : 9176J  Beximco Pharmaceuticals Ltd  29 October 2024

29 October 2024

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation 596/2014 which is part of English Law
by virtue of the European (Withdrawal) Act 2018, as amended. On publication of
this announcement via a regulatory information service, this information is
considered to be in the public domain.

 

 

BEXIMCO PHARMACEUTICALS LIMITED

 

Notification of Preliminary Results and Annual General Meeting

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM
Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical ingredients, today
announces information for shareholders of the Company that the Board of
Directors decided at their meeting held on 28 October 2024. Please see further
detail as follows:

 

 1.  To recommend the approval of the Financial Statements for the year ended 30   The Audited Financial Statements for the year ended 30 June 2024 have been
     June, 2024                                                                    approved. The full accounts are expected to be announced by 7 November 2024
 2.  Date & Time of 48(th) Annual General Meeting ("AGM") of the Company for       29 December 2024 at 10.30 A.M. Bangladesh Time
     the year ended 30 June, 2024
 3.  Venue of AGM                                                                  Virtual Platform (Zoom Meeting)

 4.  Proposed Dividend for the year ended 30 June, 2024                            40% Cash Dividend (i.e. Tk 4.00 per Share)
 5.  Record date                                                                   25 November 2024
 6.  Proposed change of Company name                                               Resolved to pass a Special Resolution to change the name of the Company from
                                                                                   "Beximco Pharmaceuticals Limited" to "Beximco Pharmaceuticals PLC" in
                                                                                   compliance to the Companies Act, 1994 (amended in 2020), subject to the
                                                                                   approval of the Shareholders in the 48th AGM of the Company to be held on 29th
                                                                                   December, 2024 as a matter of special business

 

 

Comparative Financial Disclosures:

 

Beximco Pharmaceuticals Limited and its Subsidiaries (Consolidated)

 

 Particulars                                 Year ended          Year ended

                                             30 June 2024        30 June 2023
 Net Profit after Tax                        Tk. 5,866,771,470   Tk. 4,524,468,490
 Earnings Per Share (EPS)                    Tk. 13.07           Tk. 10.34
 Net Asset Value (NAV)                       Tk. 47,949,964,744  Tk. 43,680,703,738
 Net Asset Value per share (NAVPS)           Tk. 107.48          Tk. 97.91
 Net Operating Cash Flow Per Share (NOCFPS)  Tk. 18.75           Tk. 13.64

 

 

Beximco Pharmaceuticals Limited (Stand-alone)

 

 Particulars                                 Year ended           Year ended

                                             30 June 2024         30 June 2023
 Net Profit after Tax                        Tk. 5,610,513,429    Tk.  4,588,008,908
 Earnings Per Share (EPS)                    Tk. 12.58            Tk. 10.28
 Net Asset Value (NAV)                       Tk. 47,391,484,377   Tk. 43,341,239,142
 Net Asset Value per share (NAVPS)           Tk. 106.23           Tk. 97.15
 Net Operating Cash Flow Per Share (NOCFPS)  Tk. 17.46            Tk. 12.96

 

 

For further information please visit www.beximcopharma.com
(http://www.beximcopharma.com/)  or enquire to:

 

Beximco Pharma

 

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext.20111

 

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext.20030

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott / Adam Dawes

Tel: +44 (0) 20 3368 3551 / 3555

 

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell / Sam Purewal

Tel: +44 (0) 20 3727 1000

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

 

Beximco Pharma is a leading manufacturer and exporter of medicines based in
Bangladesh. Since its inception in 1976, the Company remains committed to
health and wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics encompasses
diverse delivery systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers, sterile
ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser
solutions, oral soluble films etc. The Company also undertakes contract
manufacturing for multinational and leading global generic pharmaceutical
companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by
global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more than 50
countries. More than 5700 employees are driving the company towards achieving
its aspiration to be among the most admired companies in the world.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORPPGGAUUPCGCR